A Foot Ulcer Is a Whole-Body Diagnosis: New 5698 Patient Cohort Puts DFU Survival Back in the Cancer Conversation — But There’s Hope #DiabeticFoot #ActAgainstAmputation #ToeandFlow

We keep relearning the same lesson, and it keeps being uncomfortable. A diabetic foot ulcer is not a wound that happens to a person. It is a person whose vascular and metabolic systems have already declared themselves, and the ulcer is simply the part you can see.

A new large cohort out of Valladolid, Spain from our colleagues Del Río-Solá ML and colleagues, published online ahead of print in Advances in Wound Care — adds 5,698 more patients to that argument. These are adults with diabetes treated for active DFUs at a tertiary referral hospital, followed longitudinally for wound outcomes, survival, health care utilization, and direct hospital costs. The authors used Kaplan-Meier estimation, competing-risk regression, multivariable Cox models, and multistate modeling to map the disease trajectory rather than a single endpoint. That methodological breadth matters, because it lets them ask not just “did the patient die” but “how did they travel through the states of this disease.”

The numbers

• 290 major amputations during follow-up.
• Five-year overall survival: 61.8%. Among patients with major amputation: 32.1%.
• Mean survival after major amputation: 35.3 months, versus more than 47 months in patients without major limb loss.
• Independent predictors of mortality: increasing age, peripheral arterial disease, ischemic heart disease, end-stage renal failure, and prior major amputation.
• Male sex was the main independent predictor of major amputation in adjusted competing-risk models.
• Care was marked by high health care utilization and progressively escalating hospital costs.

A 32.1% five-year survival after major amputation belongs in the same sentence as our most feared malignancies. That is not rhetoric. It is the comparison we have been making, with receipts, for a long time now.

We have been saying this for 2 decades

This is where the Valladolid paper stops being a standalone result and becomes the newest entry in a line of evidence that is, frankly, getting hard to ignore.

In 2020, we and Padula and colleagues laid out that five-year mortality and direct costs of care for people with diabetic foot complications are comparable to cancer. The framing was deliberate. We have a societal vocabulary for cancer — urgency, screening, dedicated centers, research dollars, public empathy — and almost none of it has historically attached to the foot.

Earlier this year, our Groningen colleagues (Ghijsen SC et al., JPRAS 2026) put hard surgical numbers to the diabetic foot attack: 26% one-year mortality, 46.2% major amputation at twelve months, amputation-free survival of just 23.2% in neuroischaemic disease. Time is tissue, and tissue is life.

And the flip side — the intervention side — keeps holding up too. The Singapore DEFINITE work (Leo WZ et al., JAPMA 2026) found podiatric care associated with 69% lower mortality and better amputation-free survival across 2,798 patients. The Alberta toe-and-flow data showed regional amputation reductions of 39–56%. When we build the team, people live longer. When we don’t, the Valladolid curve is what we get.

What’s actually new here, and what should bother us

Two things from this cohort deserve a second look.

First, the multistate modeling. Most of our survival literature treats death as a single event hanging off a Kaplan-Meier curve. Modeling the transitions — ulcer to minor amputation to major amputation to death, with competing risks handled honestly — is a more faithful picture of how these patients actually move. It is also a better scaffold for deciding where to intervene, because not every transition is equally modifiable.

Second, male sex as the dominant independent predictor of major amputation. This keeps surfacing, and it sits a little awkwardly next to our usual driver list of PAD, ischemic heart disease, and renal failure. Is it biology, behavior, delayed presentation, or some interaction we haven’t named cleanly? I don’t think we know yet. It is worth more than a line in a discussion section.

The point

The authors’ conclusion is the one we should be tattooing somewhere visible: a DFU should be regarded as a marker of advanced systemic disease, not an isolated wound. The patient in front of you with a neuropathic ulcer is a cardiovascular patient, a renal patient, and a survival-curve patient who happens to have entered the system through the foot.

So we do the unglamorous things. We risk-stratify early. We check the arteries instead of assuming. We put the patient on the statin and the antiplatelet. We build the interdisciplinary team and we measure it. None of this is a potential advance in the technological sense — it is the disciplined application of what we already know to a disease that is, by these numbers, every bit as lethal as the diagnoses that frighten us more.

The foot is not the problem. The foot is the messenger. And the message, again, is mortality.

Reference: Del Río-Solá ML, García Padrón C, de la Torre Casaseca C, Álvarez García E, Brizuela Sanz JA. Diabetic Foot Ulcers as a Marker of Systemic Disease: Long-Term Survival, Limb Loss, and Economic Impact in a Large Real-World Cohort. Adv Wound Care (New Rochelle). 2026 May 31. doi:10.1177/21621918261450959. PMID: 42219280.

#DiabeticFoot #DiabeticFootUlcer #DFU #DFUmortality #Mortality #Survival #AmputationFreeSurvival #MajorAmputation #Amputation #AmputationPrevention #ActAgainstAmputation #PAD #CLTI #SystemicDisease #WorseThanCancer #LimbSalvage #LimbPreservation #VascularSurgery #WoundCare #CostOfCare #diabeticfootonline